Cancer Fighters Thrive

WINTER 2013

Cancer Fighters Thrive is a quarterly print and online magazine bringing readers practical, innovative and inspirational information about cancer treatment and survivorship.

Issue link: http://cancerfightersthrive.epubxp.com/i/197379

Contents of this Issue

Navigation

Page 55 of 55

Cancer Fighters Thrive™ c/o CTCA at Southwestern Regional Medical Center 10109 E. 79th Street Tulsa, OK 74133 SANCUSO® (Granisetron Transdermal System): A recommendation from leading treatment guidelines1,2 When preparing for chemotherapy, be armed & ready For nausea and vomiting One patch. One application. 5 days of coverage.3 Visit www.sancuso.com to learn more and to download a moneysaving co-pay card. Please refer to the sunlight warning in the important safety information below. Important safety information SANCUSO® (Granisetron Transdermal System) is indicated for the prevention of nausea and vomiting in patients receiving moderately and/or highly emetogenic chemotherapy regimens of up to 5 consecutive days duration.4 SANCUSO is contraindicated in patients with known hypersensitivity to granisetron or to any of the components of the patch.4 Granisetron may mask a progressive ileus and/or gastric distention caused by the underlying condition.4 Mild application site reactions have occurred; remove the patch if severe reaction or a generalized skin reaction occurs.4 Patients should avoid direct exposure of application site to natural or artificial sunlight by covering with clothing while wearing the patch and for 10 days after removing it.4 The most common adverse reaction in patients receiving SANCUSO is constipation (5.4%).4 SANCUSO contains granisetron.4 Healthcare professionals should avoid prescribing any additional products that contain granisetron. No clinically relevant drug interactions have been reported in clinical studies with SANCUSO.4 References: 1. National Comprehensive Cancer Network. NCCN Clinical Practice Guidelines in Oncology: Antiemesis. V.1.2012. http://www.nccn.org/ professionals/physician_gls/pdf/antiemesis.pdf. Accessed December 13, 2011. 2. Basch E, Prestrud AA, Hesketh PJ, et al. Antiemetics: American Society of Clinical Oncology Clinical Practice Guideline Update. J Clin Oncol. 2011;29(31):4189-4198. 3. Boccia RV, Gordan LN, Clark G, Howell JD, Grunberg SM; on behalf of the Sancuso Study Group. Efficacy and tolerability of transdermal granisetron for the control of chemotherapyinduced nausea and vomiting associated with moderately and highly emetogenic multi-day chemotherapy: a randomized, double-blind, phase III study. Support Care Cancer. 2011;19(10):1609-1617. 4. SANCUSO [package insert]. Bridgewater, NJ: ProStrakan, Inc; 2011. ONLY www.prostrakan-usa.com www.sancuso.com SANCUSO is a registered trademark of ProStrakan, Inc. ©2012 ProStrakan, Inc. All rights reserved. Printed in U.S.A. SAN-2012-006 February 2012 Please see brief summary of Prescribing Information on adjacent page. Keeps them covered

Articles in this issue

Links on this page

Archives of this issue

view archives of Cancer Fighters Thrive - WINTER 2013